A cost-effectiveness study comparing the as-needed use of formoterol (Oxis®) and terbutaline (Bricanyl®) in patients with moderate to severe asthma
| Autor: | BERGGREN, F a, b, f1f1Correspondence should be addressed to: Fredrik Berggren, AstraZeneca R&D Lund, Clinical Science, S-22187 Lund, Sweden. Fax: +46 46 33 75 53; E-mail: Fredrik.Berggren@astrazeneca.com, EKSTRÖM, T a, c |
|---|---|
| Zdroj: | In Respiratory Medicine September 2001 95(9):753-758 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect